Johnson & Johnson Posts Strong Q3 with $5.15B Net Earnings, Lifts 2025 Outlook
J&J posted $24B in Q3 sales and $2.80 adjusted EPS, beating estimates and raising full-year guidance.
BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
BTC$62,618.00-0.25%
ETH$1,784.25+0.38%
USDT$0.9988-0.04%
USDC$0.9999+0.01%
XRP$1.07-0.61%
SOL$75.19-1.62%
TRX$0.3249-1.59%
FIGR_HELOC$1.03+1.91%
HYPE$63.74-2.41%
DOGE$0.0723+0.10%
USDS$0.99970.00%
RAIN$0.0143-0.35%
LEO$9.54+0.05%
ZEC$507.59-1.85%
WBT$54.95-0.04%
Johnson & Johnson reported Q4 2025 revenue of $24.6 billion, beating expectations, while EPS came in at $2.46, just below forecasts.
J&J posted $24B in Q3 sales and $2.80 adjusted EPS, beating estimates and raising full-year guidance.
Johnson & Johnson (JNJ) surpassed expectations in Q2 2025 with a notable increase in earnings per share and revenue.
Johnson & Johnson's first-quarter results surpassed expectations with notable growth in sales and earnings.
Johnson & Johnson faces a significant legal setback with the dismissal of its $10 billion settlement proposal related to talc product lawsuits.
Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19.
Johnson & Johnson (NYSE: JNJ) reported a 4.3% increase in sales to $22.4 billion in Q2 2024, with operational growth at 6.6% and adjusted EPS rising…
Johnson & Johnson (NYSE: JNJ) reported a 2.3% increase in sales to $21.4 billion for Q1 2024.
Johnson & Johnson exceeded the anticipated earnings per share (EPS) of $2.28, showcasing operational efficiency and resilience in a complex global business environment.